‘Highest risk–highest benefit’ strategy: a pragmatic,...

  • Main
  • 2017 / 12
  • ‘Highest risk–highest benefit’ strategy: a pragmatic,...
European Heart Journal 2017 / 12

‘Highest risk–highest benefit’ strategy: a pragmatic, cost-effective approach to targeting use of PCSK9 inhibitor therapies

Annemans, Lieven, Packard, Chris J, Briggs, Andrew, Ray, Kausik K
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Language:
english
Journal:
European Heart Journal
DOI:
10.1093/eurheartj/ehx710
Date:
December, 2017
File:
PDF, 254 KB
english, 2017
Conversion to is in progress
Conversion to is failed